tab014
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 15, 2018 (NCT03675880)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05461339 | Phase 3 | Jun 28, 2022 | Chinese Academy of Medical Sciences, TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Pharmaceutical Limited |
| NCT03675880 | Phase 1 | Jun 15, 2018 | Chinese Academy of Medical Sciences, Lee's Pharmaceutical |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 2 | 2018 |
| Lee's Pharmaceutical | For profit | 1 | 1 | 1 | 2018 |
| TOT Biopharm Co., Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Zhaoke (Guangzhou) Pharmaceutical Limited | Government | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1